021-51111890
购物车（）
sales@molnova.cn
Tetrakis (4-carboxyphenyl) porphyrin
CAS No. 14609-54-2
Tetrakis (4-carboxyphenyl) porphyrin ( TCPP,Tetracarboxyphenylporphine )
产品货号. M22771 CAS No. 14609-54-2
四(4-羧基苯基)卟啉具有金属去除剂的作用。四(4-羧基苯基)卟啉是一种三维Ru聚合物络合物。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 25MG | ￥113 | 有现货 |
|
| 50MG | ￥151 | 有现货 |
|
| 100MG | ￥218 | 有现货 |
|
| 500MG | ￥483 | 有现货 |
|
| 1G | ￥705 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥120 | 有现货 |
|
生物学信息
-
产品名称Tetrakis (4-carboxyphenyl) porphyrin
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述四(4-羧基苯基)卟啉具有金属去除剂的作用。四(4-羧基苯基)卟啉是一种三维Ru聚合物络合物。
-
产品描述Tetrakis (4-carboxyphenyl) porphyrin plays the role of a metal remover.Tetrakis (4-carboxyphenyl) porphyrin is a fabricated three dimensional Ru polymer complex.?It can be grafted on SiO2/Nb2O5 substrate and subsequently metallized to investigate catalytic oxidation of hydrazine?tetrakis (4-carboxyphenyl) porphyrin(TCPP) displayed relatively low solubility (<0.1 mg mL-1) in a 1 M LiDFOB/PC electrolyte, high reversible specific capacity (ca. 1200 mA h g-1 at 358 mA g-1), excellent rate capability (548.4 mA h g-1 at 8 A g-1) and superior cycling performance (capacity retention of 89% after 2500 cycles at 6 A g-1).
-
体外实验——
-
体内实验——
-
同义词TCPP,Tetracarboxyphenylporphine
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number14609-54-2
-
分子量790.8
-
分子式C48H30N4O8
-
纯度>98% (HPLC)
-
溶解度DMSO:Soluble;Water:Soluble
-
SMILESC1=CC(=CC=C1C2=C3C=CC(=C(C4=NC(=C(C5=CC=C(N5)C(=C6C=CC2=N6)C7=CC=C(C=C7)C(=O)O)C8=CC=C(C=C8)C(=O)O)C=C4)C9=CC=C(C=C9)C(=O)O)N3)C(=O)O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Eun-Young Jeong, et al. Removal of Cu(II) from water by tetrakis(4-carboxyphenyl) porphyrin-functionalized mesoporous silica. J Hazard Mater. 2011 Jan 30;185(2-3):1311-7.
产品手册
关联产品
-
62'-Dihydroxyflavone
6,2'-DiHydroxyflavone 是一种新型的 GABAA 受体拮抗剂。
-
Fortunellin
Fortunellin is a natural product for research related to life sciences.
-
Copper histidine
Copper histidine inhibited Ctr1-mediated cellular uptake of oxaliplatin in vitro without altering oxaliplatin accumulation of platinum or neurotoxicity in DRG tissues in vivo. Copper histidine is administered orally for the treatment of Menkes disease.
